

(43) International Publication Date
14 July 2011 (14.07.2011)(10) International Publication Number
WO 2011/085369 A1(51) International Patent Classification:
C12Q 1/70 (2006.01) *C12N 15/86* (2006.01)(US). RUSHE, Mia, Marie [US/US]; 30 Henry Street,
Everett, MA 02149 (US).(21) International Application Number:
PCT/US2011/020832(74) Agent: HATTON, Allyson, R.; Lando & Anastasi LLP,
Riverfront Office Park, One Main Street, Suite 1100,
Cambridge, MA 02142 (US).(22) International Filing Date:
11 January 2011 (11.01.2011)(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/294,048 11 January 2010 (11.01.2010) US
61/316,193 22 March 2010 (22.03.2010) US(71) Applicant (for all designated States except US): BIO-
GEN IDEC MA INC. [US/US]; 14 Cambridge Center,
Cambridge, MA 02142 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GORELIK, Leonid
[RU/US]; 216 Parke Avenue, Quincy, MA 02171 (US).
SIMON, Kenneth, J. [US/US]; 454 Windsor Street,
Cambridge, MA 02141 (US). SUBRAMANYAM,
Meena [US/US]; 3 Corey Avenue, Stoneham, MA 02180(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: ASSAY FOR JC VIRUS ANTIBODIES




FIG. 1

(57) Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.



LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, **Published:**
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — *with international search report (Art. 21(3))*
GW, ML, MR, NE, SN, TD, TG).